ORIGINAL CONTRIBUTION. Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease
|
|
- Merry Garrett
- 6 years ago
- Views:
Transcription
1 ORIGINAL CONTRIBUTION Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease Preliminary Results D. Larry Sparks, PhD; Marwan N. Sabbagh, MD; Donald J. Connor, PhD, PhD; Jean Lopez, MSN, CNRN; Lenore J. Launer, PhD; Patrick Browne, MD; Dawn Wasser, BS; Sherry Johnson-Traver; Jeff Lochhead, BS; Chuck Ziolwolski, MS Background: Laboratory evidence of cholesterol-induced production of amyloid as a putative neurotoxin precipitating Alzheimer disease, along with epidemiological evidence, suggests that cholesterol-lowering statin drugs may favorably influence the progression of the disorder. Objective: To determine if treatment with atorvastatin calcium affects the cognitive and/or behavioral decline in patients with mild to moderate Alzheimer disease. Design: Pilot intention-to-treat, proof-of-concept, doubleblind, placebo-controlled, randomized (1:1) trial with a 1-year exposure to once-daily atorvastatin calcium (80 mg; two 40-mg tablets) or placebo using last observation carried forward analysis of covariance as the primary method of statistical assessment. Participants: Individuals with mild to moderate Alzheimer disease (Mini-Mental State Examination score of 12-28) were recruited. Of the 98 participants providing informed consent, 71 were eligible for randomization, 67 were randomized, and 63 subjects completed the 3-month visit and were considered evaluable. Main Outcome Measures: The primary outcome measures were change in Alzheimer s Disease Assessment Scale cognitive subscale and the Clinical Global Impression of Change Scale scores. The secondary outcome measures included scores on the Mini-Mental State Examination, Geriatric Depression Scale, the Neuropsychiatric Inventory Scale, and the Alzheimer s Disease Cooperative Study Activities of Daily Living Inventory. The tertiary outcome measures included total cholesterol, lowdensity lipoprotein cholesterol, and very low-density lipoprotein cholesterol levels. Results: Atorvastatin reduced circulating cholesterol levels and produced a positive signal on each of the clinical outcome measures compared with placebo. This beneficial effect reached significance for the Geriatric Depression Scale and the Alzheimer s Disease Assessment Scale cognitive subscale at 6 months and was significant at the level of a trend for the Alzheimer s Disease Assessment Scale cognitive subscale, Clinical Global Impression of Change Scale, and Neuropsychiatric Inventory Scale at 12 months assessed by analysis of covariance with last observation carried forward. Conclusion: Atorvastatin treatment may be of some clinical benefit and could be established as an effective therapy for Alzheimer disease if the current findings are substantiated by a much larger multicenter trial. Arch Neurol. 05;62: Author Affiliations: Sun Health Research Institute, Sun City, Ariz (Drs Sparks, Sabbagh, and Connor, Mss Lopez and Johnson-Traver, and Messrs Lochhead and Ziolwolski); National Institute on Aging, Bethesda, Md (Dr Launer); and Departments of Cardiology (Dr Browne) and Pharmacy (Ms Wasser), Walter O. Boswell Hospital, Sun City. ALZHEIMER DISEASE (AD) IS characterized clinically by progressive deterioration of cognitive and noncognitive abilities, culminating in profound dementia. The antemortem diagnosis of AD is confirmed by the neuropathologic presence of neurofibrillary tangles and senile plaques in sufficient numbers to meet diagnostic criteria set by convention. 1 The first hint of a relationship between cholesterol and AD stemmed from observations of enhanced prevalence of amyloid containing senile plaques among subjects without dementia with coronary artery disease compared with individuals without dementia and heart disease. 2,3 Although not a consistent finding, it has been proposed that previously elevated circulating cholesterol levels increase the risk of AD 3-fold. 4 A more recent study indicates chronically elevated cholesterol levels in midlife increase later risk of AD. 5 The cholesterol-ad relationship gained support with evidence of increased brain amyloid levels in cholesterol-fed New Zealand White rabbits as the best small-animal model of human coronary artery disease. 6,7 A potential benefit for cholesterollowering therapy in AD was clear once significant reductions in brain amyloid levels were identified after removing cholesterol from the diet of animals previously fed a cholesterol-enriched diet. 7 More recently, 753
2 some, but not all, epidemiological studies suggest that prior statin use in treating risk of coronary artery disease may reduce the risk of AD later in life We tested the cholesterol-lowering medication atorvastatin calcium for positive effects on cognitive and noncognitivedeteriorationinmildtomoderatead. Thisinvestigatorinitiated clinical evaluation began in 1999 as a proof-ofconcept trial evaluating atorvastatin for clinical benefit. We used tests of clinical efficacy (Clinical Global Impression of Changescale 11 [CGIC])andcognitivefunction(Alzheimer s DiseaseAssessmentScale cognitivesubscale 12 [ADAS-cog]) as primary outcomes and measures of global function(mini- Mental State Examination [MMSE]), psychiatric symptoms (NeuropsychiatricInventoryCaregiverDistressScale 13 [NPI]), activityofdailyliving(alzheimer sdiseasecooperativestudy Activities of Daily Living Inventory 14,15 [ADCS-ADL]), and depression severity (Geriatric Depression Scale 16 [GDS]) as secondary outcome indexes. Tertiary outcome measures included total and fractionated cholesterol levels. METHODS The study was initiated as an intention-to-treat investigation using a double-blind, placebo-controlled, randomized (1:1) design testing atorvastatin calcium (80 mg/d) compared with placebo for clinical benefit in treating mild to moderate AD for a 1-year period. As an intention-to-treat study, early withdrawals were anticipated and any subject completing the 3-month visit was considered evaluable. Written informed consent was obtained from participants and the participant s legally authorized representative or caregiver using an institutional review board approved informed consent form. We recruited 97 individuals with probable or possible AD (National Institute of Neurological and Communicative Disorders and Stroke the Alzheimer s Disease and Related Disorders Associations [NINCDS/ADRDA] criteria) 17 for this singlesite study. Individuals 5ears and older with mild to moderate impairment (MMSE score, 12-28) meeting all preestablished criteria were eligible to participate in the trial. A single dose of atorvastatin calcium (80 mg/d) without dose titration was used. Because active treatment was expected to reduce circulating cholesterol levels, all investigators were blinded to both treatment group and cholesterol profiles after randomization. Only the special physician safety monitor (P.B.), who was not involved in any other aspect of the trial, viewed quarterly cholesterol levels to ensure patient safety. Blood-borne markers of liver dysfunction and altered muscle physiologic features were also monitored quarterly by the safety monitor as indicators of possible adverse events known to accompany administration of statins. Subjects were ineligible if they were already taking a cholesterol-lowering medication or being administered an investigational treatment for AD. Atorvastatin calcium tablets (40 mg) and identical placebo tablets were supplied in bulk (single lot numbers for each, respectively) by Pfizer Pharmaceuticals, Inc (Ann Arbor, Mich). Active drug or placebo was packaged in bottles of 0 tablets (3-month supply) and provided to participants at the baseline, 3-, 6-, and 9-month visits. Randomization was performed in blocks of 10 (5 active medication and 5 placebo) using the Excel spreadsheet randomnumber generator. The randomization schedule was inspected to ensure there was no duplication of random sequences and that there were 5 individuals assigned to each treatment group (D.W.). Bottles of study medication (as 3-month supplies) were coded at the pharmacy. To participate, an individual 5ears or older, with a diagnosis of probable or possible AD according to NINCDS-ADRDA and Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for dementia and at least a ninth-grade education, was required to provide informed consent. It was necessary for the participant to be accompanied by an appropriate caregiver who could aid in administration of medication and make assessments, be of good general health as evidenced by physical, neurological, and clinical laboratory examinations, and speak English fluently. Participants were required to score 4 or less on the modified Hachinski Ischemia Scale and or less on the GDS. Participants were allowed to continue the use of stable doses of medications for the treatment of nonexcluded medical conditions for 4 weeks prior to screening; this included the use of 400 IU or lower of vitamin E. Patients currently taking cholinesterase inhibitors were required to have taken a stable dose for at least 3 months. No study subject was using memantine or allowed to initiate cholinesterase inhibitor use after trial entrance and continue participation. Individuals with a neurological or psychiatric disease other than AD, including suspected Parkinson disease or dementia with Lewy bodies, 19 significant systemic illness, organ failure, myocardial infarction, cardiac or thromboembolic vascular disease, major depression according to DSM-IV criteria, or currently using anticholinergic medications, were excluded from participation. Individuals with a history of head injury, significant liver disease and/or elevated transaminase levels, allergy to statin medications, or screen cholesterol levels below 90 (2.3 mmol/l) were also excluded from participation. At screening, the baseline MMSE was administered to ensure eligibility; if within established criteria (score 12-28), the modified Hachinski Ischemia Scale score ( 4) and the baseline GDS score ( ) 16 were established to exclude individuals with significant vascular risk factors or clinical depression, respectively. At this visit, blood was drawn for testing (experimental and safety monitoring) and the baseline ADAS-cog 12 was administered (by individuals blinded to CGIC performance). At the randomization visit, no more than 14 days after the screening visit, the baseline CGIC 11 (performed by a single individual blind to all other assessment information), NPI, 13 and ADCS-ADL 14,15 were administered. The ADAS-cog, MMSE, and CGIC were readministered at the 3-, 6-, 9-, and 12-month visits, and the NPI and ADCS- ADL were readministered at the 6- and 12-month visits. The GDS was readministered at the participant s exit visit (12- month or early termination). Fasting cholesterol (total, low-density lipoprotein, highdensity lipoprotein, and very low-density lipoprotein), liver function, and creatinine phosphokinase (to monitor muscle derangements and rhabdomyolysis) tests were performed using standard, approved methods in the Clinical Laboratory Improvement Amendments certified and accredited Clinical Chemistry Laboratory at Walter O. Boswell Hospital, Sun City, Ariz. Any individual exhibiting a greater than 3-fold increase in liver function test results or a 10-fold increase in creatinine phosphokinase level, both higher than the upper limits of normal, was considered to have experienced an adverse event requiring discontinuation of study medication without possibility of resuming trial participation. The initial statistical evaluation was to determine if there were differences in the mean value for any index between the atorvastatin and placebo groups prior to randomization (2- tailed independent t tests) (Table 1). Thereafter, we used a statistical approach routinely used in intention-to-treat AD trials 21,22 by performing analysis of covariance considering last observation carried forward data using baseline observations as a covariant to compare differences of least 754
3 squares means between the groups (SAS Version 6.12; SAS Institute Inc, Cary, NC). Screen and quarterly visit values were evaluated for the ADAS-cog, MMSE, and cholesterol. Change in CGIC scores from baseline at quarterly visits was evaluated. Baseline and semiannual visit scores were compared for the NPI and ADCS- ADL. Screening and exit scores were compared for the GDS. Significance was based on 2-tailed evaluations. RESULTS SUBJECT POPULATION AND STUDY ATTRITION We obtained 98 informed consents (Figure 1). Fifteen individuals withdrew prior to screening primarily to participate in other treatment trials. There were 12 screen failures, leaving 71 individuals eligible for randomization; 4 withdrew prior to the baseline visit. Sixty-seven individuals were blindly randomized (1:1) to receive either 80 mg of atorvastatin calcium or placebo. Sixty-three individuals were considered evaluable by completing the 3-month visit, 32 individuals receiving atorvastatin and 31 individuals receiving placebo. All but 6 individuals were taking cholinesterase inhibitors, 3 in the atorvastatin group and 3 in the placebo group. A total of 56 individuals completed the 6-month visit, 29 receiving active medication and 27 receiving placebo. Forty-eight individuals completed the 9-month visit, 26 receiving atorvastatin and 22 receiving placebo. Forty-six individuals completed the 1-year study, 25 receiving atorvastatin and 21 receiving placebo. PRERANDOMIZATION COMPARISON OF GROUP DIFFERENCES Table 1. Prerandomization Values for Each Index Among Individuals Providing Evaluable Data* Variable Placebo Group (n = 31) Atorvastatin Calcium Group (n = 32) P Value Age, y 78.9 ± ± Female, % Education, y ± ± Apo E4 1 E4 allele, % Instrument score ADAS-cog ± ± MMSE.52 ± ± NPI ± ± GDS ± ± ADCS-ADL 14, ± ± Blood marker Total cholesterol level, 8.00 ± ± LDL cholesterol level, ± ± VLDL cholesterol level, ± ± Abbreviations: ADAS-cog, Alzheimer s Disease Assessment Scale cognitive subscale; ADCS-ADL, Alzheimer s Disease Cooperative Study Activities of Daily Living Inventory; Apo E, apolipoprotein E; GDS, Geriatric Depression Scale; LDL, low-density lipoprotein; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory Caregiver Distress Scale; VLDL, very low-density lipoprotein. SI conversion factors: To convert total cholesterol to millimoles per liter, multiply by ; LDL cholesterol to millimoles per liter, *Values are expressed as mean ± SEM (based on eventual randomization grouping) unless otherwise indicated. There was no significant difference in the mean entrance values for any demographic, clinical, or chemical index between individuals later randomized into the atorvastatin and placebo groups(table 1), although performance on the NPI in the placebo group was somewhat more impaired at the start of the trial. There was no difference in the entrance Hachinski Ischemia Scale score (mean±sd, atorvastatin=2.44±0.25; placebo=2.52±0.23) between the 2 groups. 15 Withdrew Prior to Screening 8 Withdrew Prior to Visit 1 98 Informed Consents 71 Subjects Randomized 12 Screen Failures BLOOD TESTING RESULTS Consistent with results in individuals with normal cognition, atorvastatin treatment produced significant decreases in total cholesterol (Figure 2A), low-density lipoprotein cholesterol, and very low-density lipoprotein cholesterol levels (not shown) among the individuals with mild to moderate AD compared with placebo (P.01). These significant decreases relative to placebo (P.002) in total cholesterol (40%), low-density lipoprotein cholesterol (54%), and very low-density lipoprotein cholesterol (30%) levels were detected at the 3-month visit and persisted to 12 months. PRIMARY CLINICAL OUTCOME MEASURES Both the atorvastatin and placebo groups showed deterioration on the ADAS-cog at 3 months; the placebo population continued to deteriorate approximately 1 point per 63 Evaluable Subjects 32 Atorvastatin and 31 Placebo Visit 2 29 Atorvastatin and 27 Placebo Visit 3 26 Atorvastatin and 22 Placebo Visit 4 25 Atorvastatin and 21 Placebo Figure 1. Flow of subjects providing informed consent for participation in the Alzheimer s Disease Cholesterol-Lowering Treatment trial and staging of attrition. quarter thereafter (Figure 2B). Performance on the ADAScog in the atorvastatin population was approximately 3.5 points superior to the placebo group at 6 months and 12 months. Difference in ADAS-cog scores between the 755
4 A 240 Atorvastatin Calcium Placebo B P =.003 Total Cholesterol Level, ADAS-cog Error Score 22 P =. P = Screen 3 mo 6 mo Screen 3 mo 6 mo C 0.0 D 22 P = P =.41 CGIC Change Score 0.5 P =.62 P =.058 P =.07 MMSE Items Correct 19 P = mo 6 mo Screen 3 mo 6 mo E F P =.08 P =.07 P = NPI Total Score GPS Total Score mo 6 mo Screen Figure 2. Course of the effect of atorvastatin calcium vs placebo at screen/baseline and at each quarterly visit. A, Mean±SEM circulating total cholesterol levels from evaluable individuals (N=63) at screen and all visits. B, Alzheimer s Disease Assessment Scale cognitive subscale 12 (ADAS-cog) data from all evaluable individuals (N=63). Mean±SEM scores for screen and quarterly visits. C, Clinical Global Impression of Change Scale 11 (CGIC) mean±sem data for all individuals receiving study medication in the placebo and treatment groups at each visit. D, Mini-Mental State Examination (MMSE) data from all evaluable individuals (N=63). Mean±SEM scores for screen and all visits. E, Neuropsychiatric Inventory Caregiver Distress Scale 13 (NPI) (10-item) mean±sem scores from all evaluable individuals (N=63) for visits while receiving study medications. F, Geriatric Depression Scale 16 (GPS) mean±sem scores for individuals taking study medication at screen and at exit or ear. Observed means at each point (±SEM) for each treatment group are presented with corresponding significance by analysis of covariance with last observation carried forward. groups was significant at 6 months (P.003) and all but significant at 12 months (P=.055) (Table 2). A trend for a difference on the CGIC between the atorvastatin and placebo groups was achieved at both 9 (P =.058) (Figure 2C) and 12 months (P=.07) (Table 2). SECONDARY CLINICAL OUTCOME MEASURES Although performance on the MMSE in the atorvastatin group showed limited improvement after the 3-month visit (Figure 2D), the difference between the groups was 756
5 not significant (P.10) (Table 2). There was a trend for a significant difference in NPI scores between the groups (Figure 2E) at 6 months (P=.08) and 12 months (P=.07) (Table 2). Atorvastatin produced significant benefit on the GDS (P.04) (Table 2) because there was deterioration in the placebo group and improvement in the atorvastatin group (Figure 2F). Differences in performance on the ADCS-ADL between the treatment and placebo groups did not achieve significance (P.23) (Table 2). COMMENT We have found that daily administration of 80 mg of atorvastatin calcium significantly reduces circulating cholesterol levels and may have a positive effect on the progressive deterioration of cognitive function and behavior anticipated in mild to moderate AD. As a pilot proof-ofconcept study, significant differences were not expected, but benefits identified tend to support the trial s rationale based on the hypothesis that excess brain cholesterolpromoting amyloid production and subsequently the symptoms of AD come from the blood because of increased circulating levels. Although the data may seem to support a cholesterol-lowering mechanism, we must acknowledge that other physiologic effects of atorvastatin (ie, anti-inflammatory, vascular, or pleiotropic) could contribute to or produce the apparent beneficial effect. Finally, although the results clearly hold promise, this was a pilot proof-of-concept trial with a small number of participants. We believe that we provide evidence for proof of concept, and establishment of similar benefit of atorvastatin in a multicenter trial investigating the effect in a much larger population may provide proof of therapy. Two such studies are ongoing. Accepted for Publication: November 22, 04. Correspondence: D. Larry Sparks, PhD, Sun Health Research Institute, W Santa Fe Dr, Sun City, AZ (larry.sparks@sunhealth.org). Author Contributions: Study concept and design: Sparks and Connor. Acquisition of data: Sabbagh, Connor, Lopez, Browne, Wasser, Johnson-Traver, Lochhead, and Ziolwolski. Analysis and interpretation of data: Sparks and Launer. Drafting of the manuscript: Sparks and Connor. Critical revision of the manuscript for important intellectual content: Sparks, Sabbagh, Lopez, Launer, Browne, Wasser, Johnson-Traver, Lochhead, and Ziolwolski. Statistical analysis: Launer. Obtained funding: Sparks. Administrative, technical, and material support: Sparks, Sabbagh, Connor, Lopez, Browne, Wasser, Johnson-Traver, Lochhead, and Ziolwolski. Study supervision: Sparks. Funding/Support: This study was supported by the Institute for the Study of Aging, the Estee Lauder Charitable Trust, and Pfizer Inc, New York, NY. Acknowledgment: We thank the Institute for the Study of Aging and the Estee Lauder Charitable Trust for making this study possible by providing initial funding. We thank Pfizer Inc for provision of additional funding and study medication. Table 2. Significance of Difference After 12 Months of Atorvastatin Treatment Compared With Placebo for Each Clinical Instrument* Instrument ANCOVA-LOCF P Value CGIC ADAS-cog NPI MMSE.25 GDS ADCS-ADL 14,15.23 Abbreviations: ADAS-cog, Alzheimer s Disease Assessment Scale cognitive subscale; ADCS-ADL, Alzheimer s Disease Cooperative Study Activities of Daily Living Inventory; ANCOVA, analysis of covariance; CGIC, Clinical Global Impression of Change Scale; GDS, Geriatric Depression Scale; LOCF, last observation carried forward; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory Caregiver Distress Scale. *Values are based on a 2-tailed assessment of least squares means by ANCOVA with LOCF for evaluable subjects. Atorvastatin was given as atorvastatin calcium. REFERENCES 1. Newell KL, Hyman BT, Growdon JH, Hedley-Whyte ET. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer s disease. J Neuropathol Exp Neurol. 1999;58: Sparks DL, Hunsaker JC, Scheff SW, et al. Cortical senile plaques in coronary artery disease, aging and Alzheimer s disease. Neurobiol Aging. 1990;11: Sparks DL, Liu H, Scheff SW, Coyne CM, Hunsaker JC III. Temporal sequence of plaque formation in the cerebral cortex of non-demented individuals. J Neuropathol Exp Neurol. 1993;52: Notkola I-L, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon4 allele, and Alzheimer s disease. Neuroepidemiology. 1998;17: Kivipelto M, Helkala E-L, Hallikainen M, et al. Midlife vascular risk factors and Alzheimer s disease in later life. BMJ. 01;322: Sparks DL, Scheff SW, Hunsaker JC III, et al. Induction of Alzheimer-like -amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994;126: Sparks DL. Intraneuronal -amyloid immunoreactivity in the CNS. Neurobiol Aging. 1996;17: Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 02;59: Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 00;356: Wolozin B, Kellman W, Ruosseau P, Celesia G, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 00;57: Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer s Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord. 1997;11:S22-S Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer s disease. Am J Psychiatry. 1984;141: Kaufer DI, Cummings JL, Cristine EL. Assessing the impact of neuropsychiatric symptoms in Alzheimer s disease. J Am Geriatr Soc. 1998;46: Galasko D, Corey-Bloom J, Thal LJ. Monitoring progression in Alzheimer s disease. J Am Geriatr Soc. 1991;39: Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer s disease. Alzheimer Dis Assoc Disord. 1997; 11:S33-S Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull. 1988;24: McKhann G, Drachman D, Folstein M. Clinical diagnosis of Alzheimer s disease. Neurology. 1984;34: Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980;7: McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47: Folstein MF, Folstein SE, McHugh PR. Mini-Mental State. J Psychiatr Res. 1975; 12: Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression. JAMA. 03;289: Aisen P. Randomized pilot study of nimesulide treatment in Alzheimer s disease. Neurology. 02;58:
Supplementary Online Content
Supplementary Online Content Atri A, Frölich L, Ballard C, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on in cognition in patients with Alzheimer disease: three randomized clinical
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationThe Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive Impairment
Journal of Gerontology: MEDICAL SCIENCES 2002, Vol. 57A, No. 7, M414 M418 Copyright 2002 by The Gerontological Society of America The Impact of the Use of Statins on the Prevalence of Dementia and the
More informationORIGINAL CONTRIBUTION. Response of Patients With Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression
ORIGINAL CONTRIBUTION Response of Patients With Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression Martin R. Farlow, MD; Ann Hake, MD; John Messina, PharmD; Richard
More informationKnown as both a thief and murderer,
&A Dementia Drugs: When Should They Be Stopped? Ron Keren, MD, FRCPC As presented at the University of Toronto s Primary Care Conference, Toronto, Ontario (May 25) Known as both a thief and murderer, Alzheimer
More informationThe Reliability and Validity of the Korean Instrumental Activities of Daily Living (K-IADL)
The Reliability and Validity of the Korean Instrumental Activities of Daily Living (K-IADL Sue J. Kang, M.S., Seong Hye Choi, M.D.*, Byung H. Lee, M.A., Jay C. Kwon, M.D., Duk L. Na, M.D., Seol-Heui Han
More informationStatins and Cognition A Focus on Mechanisms
Statins and Cognition A Focus on Mechanisms Note: Deleted copyrighted graphs/tables are described In red text and source references are provided Disclosures: SPARCL Steering Committee and past consultant
More informationMonth/Year of Review: September 2013 Date of Last Review: February 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationCLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD. Statin Use and the Risk of Incident Dementia
CLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD Statin Use and the Risk of Incident Dementia The Cardiovascular Health Study Thomas D. Rea, MD, MPH; John C. Breitner, MD; Bruce M. Psaty, MD, PhD; Annette
More informationORIGINAL CONTRIBUTION. Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women
ORIGINAL CONTRIBUTION Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women Kristine Yaffe, MD; Elizabeth Barrett-Connor, MD; Feng Lin, MS; Deborah Grady, MD Background: Few strategies
More informationORIGINAL INVESTIGATION. Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease
Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease The Framingham Study ORIGINAL INVESTIGATION Zaldy Sy Tan, MD, MPH; Sudha Seshadri, MD; Alexa Beiser, PhD; Peter W. F. Wilson, MD; Douglas
More informationDementia of the Alzheimer Type: the Drug Treatment Debate
Dementia of the Alzheimer Type: the Drug Treatment Debate I have no financial conflict of interest. Many years ago I was given a trip to San Fran and taught to use a slide set from the drug company. I
More informationC holinomimetic drugs constitute the first line of treatment
310 PAPER Cholinesterase inhibitor treatment alters the natural history of Alzheimer s disease O L Lopez, J T Becker, S Wisniewski, J Saxton, D I Kaufer, S T DeKosky... See end of article for authors affiliations...
More informationNEXT-Link DEMENTIA. A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES.
NEXT-Link DEMENTIA A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES. NEXT-Link DEMENTIA NEXT-Link DEMENTIA is a network of Danish
More informationThe Development and Validation of Korean Dementia Screening Questionnaire (KDSQ)
The Development and Validation of Korean Dementia Screening Questionnaire (KDSQ) Dong Won Yang, M.D., Belong Cho, M.D.*, Jean Yung Chey, Ph.D., Sang Yun Kim, M.D., Beum Saeng Kim, M.D. Department of Neurology,
More informationTrial Designs and Outcomes to Monitor Novel Therapeutics in Alzheimer s Disease
2 Trial Designs and Outcomes to Monitor Novel Therapeutics in Alzheimer s Disease Serge Gauthier Introduction The various etiological hypotheses for Alzheimer s disease (AD) need to be tested in patients
More informationIan McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University
Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Design of trials in DLB and PDD What has been learnt from previous trials in these indications and other dementias? Overview
More informationBaseline Characteristics of Patients Attending the Memory Clinic Serving the South Shore of Boston
Article ID: ISSN 2046-1690 Baseline Characteristics of Patients Attending the www.thealzcenter.org Memory Clinic Serving the South Shore of Boston Corresponding Author: Dr. Anil K Nair, Chief of Neurology,
More informationAnosognosia, or loss of insight into one s cognitive
REGULAR ARTICLES Anosognosia Is a Significant Predictor of Apathy in Alzheimer s Disease Sergio E. Starkstein, M.D., Ph.D. Simone Brockman, M.A. David Bruce, M.D. Gustavo Petracca, M.D. Anosognosia and
More informationManagement of cognition and function: new results from the clinical trials programme of Aricept (donepezil HCl)
International Journal of Neuropsychopharmacology (2000), 3 (Supplement 2), S13 S20. Copyright 2000 CINP Management of cognition and function: new results from the clinical trials programme of Aricept (donepezil
More informationT he prevalence of Parkinson s disease (PD) is nearly 1% in
708 PAPER Donepezil for cognitive impairment in Parkinson s disease: a randomised controlled study D Aarsland, K Laake, J P Larsen, C Janvin... See end of article for authors affiliations... Correspondence
More informationCLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD. Efficacy of Donepezil in Early-Stage Alzheimer Disease
CLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD Efficacy of Donepezil in Early-Stage Alzheimer Disease A Randomized Placebo-Controlled Trial Ben Seltzer, MD; Parvaneh Zolnouni, MD; Margarita Nunez, MD;
More informationThe course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry 2005; 20: 531 536. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/gps.1317 The course of neuropsychiatric
More informationUse of statins and incidence of dementia and cognitive impairment without dementia in a cohort study
Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study Fn1 C. Cramer, PhD M.N. Haan, DrPH S. Galea, MD, DrPH K.M. Langa, MD, PhD J.D. Kalbfleisch, PhD Address
More informationTreatment of AD with Stabilized Oral NADH: Preliminary Findings
MS # 200 000 128 Treatment of AD with Stabilized Oral NADH: Preliminary Findings G.G. Kay, PhD, V. N. Starbuck, PhD and S. L. Cohan, MD, PhD Department of Neurology, Georgetown University School of Medicine
More informationPrevalence and Impact of Medical Comorbidity in Alzheimer s Disease
Journal of Gerontology: MEDICAL SCIENCES 2002, Vol. 57A, No. 3, M173 M177 Copyright 2002 by The Gerontological Society of America Prevalence and Impact of Medical Comorbidity in Alzheimer s Disease P.
More informationA 24-Week, Open-Label Extension Study to Investigate the Long-Term Safety,
1 A 24-Week, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer s Disease Martin R. Farlow,
More informationEXPEDITION3: A Phase 3 Trial of Solanezumab in Mild Dementia due to Alzheimer s Disease
EXPEDITION3: A Phase 3 Trial of in Mild Dementia due to Alzheimer s Disease Lawrence S. Honig, MD, PhD On behalf of the EXPEDITION3 Study Team Disclosure Statement I will discuss investigational use only.
More informationClinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease
Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top
More informationORIGINAL CONTRIBUTION. Diagnostic Validity of the Dementia Questionnaire for Alzheimer Disease
ORIGINAL CONTRIBUTION Diagnostic Validity of the Dementia Questionnaire for Alzheimer Disease Ronald J. Ellis, MD, PhD; Kaining Jan, MD; Claudia Kawas, MD; William C. Koller, MD; Kelly E. Lyons, PhD; Dilip
More informationANTIOXIDANT SUPPLEMENTS IN ALZHEIMER S DEMENTIA AND MILD COGNITIVE IMPAIRMENT: A SYSTEMATIC REVIEW
Journal of Aging Research & Clinical Practice Volume 6, 2017 J Aging Res Clin Practice 2017;6:1-8 Published online December 1, 2016, http://dx.doi.org/10.14283/jarcp.2016.121 ANTIOXIDANT SUPPLEMENTS IN
More informationORIGINAL CONTRIBUTION. Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment
ORIGINAL CONTRIBUTION Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment David F. Tang-Wai, MDCM; David S. Knopman, MD; Yonas E. Geda, MD;
More informationSCIENTIFIC DISCUSSION
London, 2 March 2006 Product name: Prometax Procedure number: EMEA/H/C/255/II/33 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86
More informationThe most common cause of dementia in the elderly is. Cholinesterase Inhibitors in the Treatment of Dementia REVIEW ARTICLE. Jay M.
Cholinesterase Inhibitors in the Treatment of Dementia Jay M. Ellis, DO Dementia associated with probable Alzheimer s disease (AD) is one of the most common types of dementia. Patients with AD often have
More informationORIGINAL ARTICLE Neuroscience INTRODUCTION MATERIALS AND METHODS
ORIGINAL ARTICLE Neuroscience DOI: 10.46/jkms.2010.25.7.1071 J Korean Med Sci 2010; 25: 1071-1076 Seoul Neuropsychological Screening Battery-Dementia Version (SNSB-D): A Useful Tool for Assessing and Monitoring
More informationTitle of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
SYNOPSIS Name of Sponsor/Company Name of Finished Product REMINYL Name of Active Ingredient(s) Galantamine hydrobromide Issue Date: 18 October 2013 Protocol No.: Title of Study: Evaluation of Efficacy
More informationRESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH
EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of
More informationThe long-term efficacy and tolerability of donepezil in patients with vascular dementia
RESEARCH ARTICLE The long-term efficacy and tolerability of donepezil in patients with vascular dementia David Wilkinson 1, Gustavo Róman 2, Stephen Salloway 3, Jane Hecker 4, Karyn Boundy 5, Dinesh Kumar
More informationORIGINAL CONTRIBUTION. An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease
ORIGINAL CONTRIBUTION An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease Yaakov Stern, PhD; Diane Jacobs, PhD; James Goldman, MD; Estrella Gomez-Tortosa, PhD; Bradley
More informationWHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient
DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of
More informationNEUROPSYCHOMETRIC TESTS
NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract
More informationThe efficacy of Rivastigmine in the management of the behavioral and psychological symptoms of lewy body dementia- a review of literature
Review article: The efficacy of Rivastigmine in the management of the behavioral and psychological symptoms of lewy body dementia- a review of literature Dr. Ivan Netto 1, Aditya Iyer 2, Dr. Prathamesh
More informationNeuropsychiatric disturbances such as delusions,
Differential Neuropsychiatric Responses to Tacrine in Alzheimer s Disease: Relationship to Dementia Severity Daniel Kaufer, M.D. Jeffrey L. Cummings, M.D. Dianne Christine, R.N. Neuropsychiatric symptom
More informationValidity of Family History for the Diagnosis of Dementia Among Siblings of Patients With Late-onset Alzheimer s Disease
Genetic Epidemiology 15:215 223 (1998) Validity of Family History for the Diagnosis of Dementia Among Siblings of Patients With Late-onset Alzheimer s Disease G. Devi, 1,3 * K. Marder, 1,3 P.W. Schofield,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal
More informationChapter 1. Introduction
The older people get, the bigger the chance of losing cognitive abilities and ultimately to develop dementia. Increasing age is the largest known risk factor of dementia, with a prevalence of 1% in people
More informationNutrition and Water for Dementia Prevention
台日生技醫藥研討會 - 自然療法於失智症預防及照護之應用 Nutrition and Water for Dementia Prevention 胡朝榮 Chaur-Jong Hu, M.D. Professor and Direction, Department of Neurology and Dementia Center, Shuang Ho Hospital, Taipei Medical
More informationResponder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch
Molinuevo et al. Alzheimer's Research & Therapy (2015) 7:9 DOI 10.1186/s13195-014-0088-8 RESEARCH Open Access Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine
More informationCity, University of London Institutional Repository
City Research Online City, University of London Institutional Repository Citation: Hurt, C. S., Banerjee, S., Tunnard, C., Whitehead, D. L., Tsolaki, M., Mecocci, P., Kloszewska, I., Soininen, H., Vellas,
More informationMild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
More informationORIGINAL CONTRIBUTION. Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
ORIGINAL CONTRIBUTION Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease Miia Kivipelto, MD, PhD; Tiia Ngandu, BM; Laura Fratiglioni, MD, PhD; Matti Viitanen, MD,
More informationCholesterol targets and therapy Thomas C. Andrews, MD, FACC
Cholesterol targets and therapy Thomas C. Andrews, MD, FACC 2 Statins in secondary prevention Still first line therapy! First line therapy: high intensity statin Dose individualized based on baseline LDL
More informationORIGINAL ARTICLE. Early and Widespread Cholinergic Losses Differentiate Dementia With Lewy Bodies From Alzheimer Disease
ORIGINAL ARTICLE Early and Widespread Cholinergic Losses Differentiate Dementia With Lewy Bodies From Alzheimer Disease Pietro Tiraboschi, MD; Larry A. Hansen, MD; Michael Alford, BA; Annette Merdes, MD;
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationThe Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer s disease
J. Sleep Res. (2003) 12, 331 337 The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer s disease ROCHELLE E. TRACTENBERG 1, CLIFFORD M. SINGER 2, JEFFREY
More informationConcept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias
15 March 20122 EMA/CHMP/60715/2012 Committee for Medicinal Products for Human Use (CHMP) Concept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease
More informationComparison of cognitive decline between dementia with Lewy bodies and Alzheimer s disease: a cohort study
Open Access To cite: Walker Z, McKeith I, Rodda J, et al. Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer s disease: a cohort study. BMJ Open 2012;2:e000380. doi:10.1136/
More informationPredictors of disease course in patients with probable Alzheimer's disease
Article abstract-the presence of extrapyramidal signs or psychosis may indicate greater disability in patients with probable Alzheimer's disease. We evaluated the ability of these signs, noted at a patient's
More informationPentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer s disease
J Neurol Neurosurg Psychiatry 2001;70:483 488 483 Center for Alzheimer Disease and Related Disorders, Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA
More informationAssociation of statin use with risk of dementia: A meta-analysis of prospective cohort studies
bs_bs_banner Geriatr Gerontol Int 2013; 13: 817 824 REVIEW ARTICLE Association of statin use with risk of dementia: A meta-analysis of prospective cohort studies Yu Song, 1 Hongwei Nie, 2 * Yong Xu, 1
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION Patient s Rating of Cognitive Ability Using the AD8, a Brief Informant Interview, as a Self-rating Tool to Detect Dementia James E. Galvin, MD, MPH; Catherine M. Roe, PhD; Mary A.
More informationTHE ASSOCIATION BETWEEN CHOLESTEROL LEVELS AND BRACHIAL/AORTIC AUGMENTATION INDEX VERSUS COGNITIVE STATUS IN PATIENTS WITH CARDIOVASCULAR RISK FACTORS
Arch. Biol. Sci., Belgrade, 64 (2), 419-426, 2012 DOI:10.2298/ABS1202419J THE ASSOCIATION BETWEEN CHOLESTEROL LEVELS AND BRACHIAL/AORTIC AUGMENTATION INDEX VERSUS COGNITIVE STATUS IN PATIENTS WITH CARDIOVASCULAR
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION Plasma Levels of -Amyloid (1-4), -Amyloid (1-42), and Total -Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins Kina Höglund, MSc;
More informationPredicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of Alzheimer s Disease
Predicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of Alzheimer s Disease Debby Tsuang, MD, MSc, Kate Simpson, MPH, Eric B. Larson, MD, MPH, Elaine Peskind, MD, Walter Kukull,
More informationIt is only in the past decade that pharmacologic
IS THERE TREATMENT FOR ALZHEIMER S DISEASE? Gary M. Levin, PharmD, BCPP, FCCP * ABSTRACT There are now 5 approved drugs for the primary symptoms of Alzheimer s disease (AD), 4 of which inhibit acetylcholinesterase
More informationResearch. Attainment of treatment goals by people with Alzheimer s disease receiving galantamine: a randomized controlled trial
Attainment of treatment goals by people with Alzheimer s disease receiving galantamine: a randomized controlled trial Kenneth Rockwood, Sherri Fay, Xiaowei Song, Chris MacKnight, Mary Gorman, on behalf
More informationThe Top Articles of Dov Gandell MDCM, FRCPC October 31, 2014.
The Top Articles of 2014 Dov Gandell MDCM, FRCPC October 31, 2014. Disclosure Statements Faculty: Dov Gandell Relationships with commercial interests: No commercial or industry disclosures Final assessment:
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-AUS-5 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral and psychological symptoms in dementia: a multicenter, double-blind,
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by From Brains at Risk to Cognitive Dysfunction: The Role of Vascular Pathology Ralph Sacco, MD, MS, FAHA, FAAN Miller School of Medicine
More informationDisclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
More informationBrain Bank of the Brazilian Aging Brain Study Group a Collection Focused in Human Control Cases
Brain Bank of the Brazilian Aging Brain Study Group a Collection Focused in Human Control Cases Lea Tenenholz Grinberg, M.D, Ph.D Associate Professor of Pathology University of the City of São Paulo Medical
More informationS ubjects with mild cognitive impairment (MCI) often
1348 PAPER Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer s disease? P J Visser, P Scheltens, F R J Verhey... See end of article for authors affiliations... Correspondence
More informationAssociation of statin use with cognitive decline in elderly African Americans
Association of statin use with cognitive decline in elderly African Americans S.J. Szwast, MD H.C. Hendrie, MB, ChB, DSc K.A. Lane, MS S. Gao, PhD S.E. Taylor, MA F. Unverzagt, PhD J. Murrell, PhD M. Deeg,
More informationSupplementary online data
THELANCETNEUROLOGY-D-07-00083 Supplementary online data MRI assessments MRI at each site included a volumetric spoiled gradient echo (T1-weighted) sequence with slice partition thickness of 1 5 mm or less
More informationLU:research Institutional Repository of Lund University
LU:research Institutional Repository of Lund University This is an author produced version of a paper published in International journal of geriatric psychiatry. This paper has been peer-reviewed but does
More informationLiterature Scan: Alzheimer s Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationK. Kahle-Wrobleski 1, J.S. Andrews 1, M. Belger 2, S. Gauthier 3, Y. Stern 4, D.M. Rentz 5, D. Galasko 6
The Journal of Prevention of Alzheimer s Disease - JPAD Volume 2, Number 2, 2015 Clinical and Economic Characteristics of Milestones along the Continuum of Alzheimer s Disease: Transforming Functional
More information2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More informationORIGINAL CONTRIBUTION. Diagnostic Accuracy of Dementia With Lewy Bodies. to be the second
ORIGINAL CONTRIBUTION Diagnostic Accuracy of Dementia With Lewy Bodies Ursula Hohl, MD; Pietro Tiraboschi, MD; Lawrence A. Hansen, MD; Leon J. Thal, MD; Jody Corey-Bloom, MD, PhD Background: Diagnostic
More informationThe Primary Care Guide To Understanding The Role Of The Metabolic Syndrome In Cognitive Decline Of Older Persons
The Primary Care Guide To Understanding The Role Of The Metabolic Syndrome In Cognitive Decline Of Older Persons 1. Defining the Metabolic Syndrome A Primary care practice often includes numerous patients
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationEvaluation of Preventive Care Program for Cognitive Function Decline among Community-dwelling Frail Elderly People A Pilot Study
Journal of Japan Academy of Community Health Nursing Vol. 9, No. 2, pp. 87 92, 2007 Evaluation of Preventive Care Program for Cognitive Function Decline among Community-dwelling Frail Elderly People A
More informationEstimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale
Estimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale Seong Hye Choi, M.D.*, Duk L. Na, M.D., Byung Hwa Lee, M.A., Dong-Seog Hahm, M.D., Jee Hyang Jeong, M.D.,
More informationIssues to Consider in the Clinical Evaluation and Development of Drugs for Alzheimer s Disease. The University of Tokyo Hospital
Project to Promote the Development of Innovative Pharmaceuticals, Medical Devices, and Regenerative Medical Products (Ministry of Health, Labour, and Welfare) Regulatory Science Research for the Establishment
More informationPrevention, health promotion & early intervention in dementia
Prevention, health promotion & early intervention in dementia Alzheimer New Zealand Conference 2014 Steve Iliffe Professor of Primary Care & Older People University College London Rotorua, New Zealand
More informationMini Nutritional Assessment and Alzheimer Patients
Mini Nutritional Assessment (MNA): Research and Practice in the Elderly: B. Vellas; P.J. Garry; Y. Guigoz (eds), Nestlé Nutrition Workshop Series Clinical & Performance Programme, Vol. 1, pp. 87 92, Nestec
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationA prospective study of dementia with Lewy bodies
Age and Ageing 998; 27: 6-66 998, British Geriatrics Society A prospective study of dementia with Lewy bodies CLIVE G. BALLARD, JOHN O'BRIEN, KATH LOWERX GARETH A. AYRE, RICHARD HARRISON, ROBERT PERRY,
More informationDonepezil, (R,S)-1-benzyl-4[(5,6 dimethoxy-1-indanon)- Update on Alzheimer Drugs (Donepezil) ORIGINAL ARTICLE. Rachelle Smith Doody, MD, PhD
ORIGINAL ARTICLE Update on Alzheimer Drugs (Donepezil) Rachelle Smith Doody, MD, PhD Background: Several clinical trials have been conducted over a period of many years reporting the benefits of donepezil
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationSafety and Efficacy of Oral Physostigmine in the Treatment of Alzheimer Disease
Clinical Neuropharmacology Vol. 16, No. 1, pp. 61--09 1993 Raven Press, Ltd., New York Safety and Efficacy of Oral Physostigmine in the Treatment of Alzheimer Disease *:j: Mary Sano, *:j:karen Bell, *:j:
More informationWorldwide, over 40 million people have. Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms
The Journal of Prevention of Alzheimer s Disease - JPAD Volume 6, Number 1, 2019 Original Research The Author(s) Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced
More informationCholinesterase inhibitors for Alzheimer s disease (Review)
Birks J This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2008, Issue 3 http://www.thecochranelibrary.com 1 T A B L E O
More informationBehavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients
Blackwell Science, LtdOxford, UKPCNPsychiatry and Clinical Neurosciences1323-13162005 Blackwell Publishing Pty Ltd593274279Original ArticleDementia and mild AlzheimersJ. Shimabukuro et al. Psychiatry and
More information